SELLAS Life Sciences Group, Inc. (SLS) Reports Preclinical SLS009 Activity in PDAC Models

Less than 1 min read

Key points:

- SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model -

- Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -

- SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology -

SELLAS reported preclinical data showing SLS009 (CDK9 inhibitor) activity in MYC‑amplified pancreatic cancer organoid models, including a daraxonrasib‑resistant model, and synergy with BET inhibitor ZEN3694.

Material Details

| # | Detail | AI Analyst View |

|---|---|---|

| 1 | SLS009 active in MYC‑amplified PDAC models | Signals potential path to address hard‑to‑treat PDAC subsets tied to MYC. |

| 2 | Activity in daraxonrasib‑resistant model | Addresses resistance to a newly approved RAS inhibitor, expanding...